GlassScriptPhysician profile
Ciara June White
NPI 1407517923
$1,720.72
in general payments reported to CMS, 2019-2025
23 companies · $624 in 2025
The $624 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $277 · 2024: $820 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $267.34 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $222.72 | 2023-2025 | Caplyta |
| Gilead Sciences, INC. | $156.29 | 2024-2025 | Epclusa |
| Pfizer INC. | $125.63 | 2023-2025 | |
| Abbott Laboratories | $115.44 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $113.19 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $81.20 | 2024-2025 | Ingrezza |
| Braeburn INC. | $73.21 | 2024 | Brixadi |
| Ironshore Pharmaceuticals INC. | $68.46 | 2023-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $68.17 | 2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Indivior INC. | $68.03 | 2024 | Sublocade |
| Exact Sciences Corporation | $61.35 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $60.46 | 2023-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $44.46 | 2024 | Austedo Xr |
| Organon LLC | $37.72 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.50 | 2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $23.51 | 2025 | |
| Alkermes, INC. | $20.48 | 2025 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $19.65 | 2023 | Pediarix, Bexsero |
| Lexicon Pharmaceuticals, INC. | $18.53 | 2024 | |
| Phadia US INC. | $18.41 | 2024 | Immunocap |
| E.R. Squibb & Sons, L.L.C. | $18.30 | 2025 | Cobenfy |
| Verona Pharma, INC. | $13.67 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciara White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.